Astellas Pharma Inc. and UMN Pharma Inc. today announced that the favorable immunogenicity and tolerability have been observed in Phase I/II clinical trial for the seasonal influenza HA vaccine UMN-0502 (ASP7374). Astellas has been pursuing drug development of this vaccine in cooperation with UMN.